254 related articles for article (PubMed ID: 24000170)
1. Naphthyridines as novel BET family bromodomain inhibitors.
Mirguet O; Lamotte Y; Chung CW; Bamborough P; Delannée D; Bouillot A; Gellibert F; Krysa G; Lewis A; Witherington J; Huet P; Dudit Y; Trottet L; Nicodeme E
ChemMedChem; 2014 Mar; 9(3):580-9. PubMed ID: 24000170
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
[TBL] [Abstract][Full Text] [Related]
3. Metabolically Derived Lysine Acylations and Neighboring Modifications Tune the Binding of the BET Bromodomains to Histone H4.
Olp MD; Zhu N; Smith BC
Biochemistry; 2017 Oct; 56(41):5485-5495. PubMed ID: 28945351
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
[TBL] [Abstract][Full Text] [Related]
5. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
[TBL] [Abstract][Full Text] [Related]
6. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
8. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the human BRD2 bromodomain: insights into dimerization and recognition of acetylated histone H4.
Nakamura Y; Umehara T; Nakano K; Jang MK; Shirouzu M; Morita S; Uda-Tochio H; Hamana H; Terada T; Adachi N; Matsumoto T; Tanaka A; Horikoshi M; Ozato K; Padmanabhan B; Yokoyama S
J Biol Chem; 2007 Feb; 282(6):4193-201. PubMed ID: 17148447
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
Chung CW; Dean AW; Woolven JM; Bamborough P
J Med Chem; 2012 Jan; 55(2):576-86. PubMed ID: 22136404
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
[TBL] [Abstract][Full Text] [Related]
12. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.
Wang J; Erazo T; Ferguson FM; Buckley DL; Gomez N; Muñoz-Guardiola P; Diéguez-Martínez N; Deng X; Hao M; Massefski W; Fedorov O; Offei-Addo NK; Park PM; Dai L; DiBona A; Becht K; Kim ND; McKeown MR; Roberts JM; Zhang J; Sim T; Alessi DR; Bradner JE; Lizcano JM; Blacklow SC; Qi J; Xu X; Gray NS
ACS Chem Biol; 2018 Sep; 13(9):2438-2448. PubMed ID: 30102854
[TBL] [Abstract][Full Text] [Related]
13. The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.
Dittmann A; Werner T; Chung CW; Savitski MM; Fälth Savitski M; Grandi P; Hopf C; Lindon M; Neubauer G; Prinjha RK; Bantscheff M; Drewes G
ACS Chem Biol; 2014 Feb; 9(2):495-502. PubMed ID: 24533473
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
[TBL] [Abstract][Full Text] [Related]
15. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.
Gosmini R; Nguyen VL; Toum J; Simon C; Brusq JM; Krysa G; Mirguet O; Riou-Eymard AM; Boursier EV; Trottet L; Bamborough P; Clark H; Chung CW; Cutler L; Demont EH; Kaur R; Lewis AJ; Schilling MB; Soden PE; Taylor S; Walker AL; Walker MD; Prinjha RK; Nicodème E
J Med Chem; 2014 Oct; 57(19):8111-31. PubMed ID: 25249180
[TBL] [Abstract][Full Text] [Related]
16. Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Kim KH; Wissner A; Floyd MB; Fraser HL; Wang YD; Dushin RG; Hu Y; Olland A; Guo B; Arndt K
Bioorg Med Chem Lett; 2009 Sep; 19(17):5225-8. PubMed ID: 19628388
[TBL] [Abstract][Full Text] [Related]
17. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
18. Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains.
Arole AH; Deshmukh P; Sridhar A; Padmanabhan B
Acta Crystallogr F Struct Biol Commun; 2022 Mar; 78(Pt 3):119-127. PubMed ID: 35234137
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
